Close Menu

NEW YORK – Biocept said today that it received a notice from Nasdaq last week that it has failed to comply with a minimum bid price rule, which requires that companies listed on the Nasdaq Capital Market maintain a minimum closing bid price of at least $1.00 per share. As a result, it could face delisting action.

The firm has a 180 calendar-day grace period to regain compliance, by maintaining a minimum closing bid price for its stock of at least $1.00 per share for a minimum of 10 consecutive business days during the 180-calendar-day grace period.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.

Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.

Stat News reports some health tech startups are laying off or furloughing workers.

In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.